JMP Securities Downgrades ARIAD Pharmaceuticals (ARIA) to Market Perform
- S&P little changed as energy weighs but financials edge up
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- Fed's Yellen says 'makes sense' to gradually raise interest rates
- UPDATE: Fed Beige Book: Wages gain modestly in most areas amid tight job market
- Mallinckrodt (MNK) Announces FTC Settlement
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
JMP Securities downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Market Outperform to Market Perform.
Shares of ARIAD Pharmaceuticals closed at $9.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- Morgan Stanley Downgrades Equifax (EFX) to Equalweight
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesJMP Securities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!